How much should we be scared of the recent gap down in CSL's (ASX: CSL) share price?
CSL Limited’s recent gap down reflects a sharp reset in market confidence rather than a collapse in its core business. The fall was driven by weaker-than-expected H1 FY26 results, plasma division margin pressure, policy headwinds in the US and China, a surprise CEO change, and earlier guidance cuts. While the stock is technically in a clear downtrend and deeply oversold, the long-term investment case now hinges on execution, margin recovery, and whether management can rebuild credibility.
Ansell Limited (ASX: ANN) – Margin Recovery and Attractive Long-Term Support Zone
We argue that despite cyclical and integration risks, Ansell’s improving margins and disciplined capital execution support a stable medium-term outlook. Technically and fundamentally, the A$28–30 range appears to represent a key support zone and a potentially attractive long-term entry level, provided earnings stability is maintained.
Has PolyNovo's (ASX: PNV) share price hit the bottom yet?
PolyNovo Limited (ASX: PNV) remains a fundamentally strong, high-growth medtech, but its share price is currently testing key support around A$0.88–0.92 within a broader sideways range. While selling pressure has eased and momentum is stabilising, a confirmed bottom would require a sustained break above A$1.08; otherwise, a fall below A$0.86–0.90 could signal further downside.
Is 4DMedical (ASX: 4DX) the Next High-Growth MedTech Breakout or a Funding Risk?
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Why Cochlear's (ASX: COH) share price keeps crashing, and where can it find a bottom?
Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
Lumos Diagnostics (ASX: LDX) Shares Keep Sliding Despite Last Year’s Rally
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.